natgillin/translations-raw huggingface dataset:
Most of these reactions resolved spontaneously without any treatment.
Večina teh reakcij izzveni spontano brez zdravljenja.
• made of a heavy-duty plastic;
• je izdelan iz trpežne plastike;
• Most of these reactions are mild to moderate and resolve on their own within a day.
• Večina teh reakcij je blagih do zmernih in v enem dnevu same izzvenijo.
If you feel tired, dizzy, or unwell after having Remsima, do not drive or use any tools or machines.
Če se po prejemu zdravila Remsima počutite utrujeni, omotični ali se ne počutite dobro, ne smete voziti ali upravljati kakršnih koli orodij ali strojev.
• improve your physical function.
• izboljšanje funkcije sklepov.
This will depend on your disease, weight and how well you respond to Remsima.
To bo odvisno od vaše bolezni, telesne mase in tega, kako se odzivate na zdravilo Remsima.
• It is recommended that when Remsima is prepared for infusion, it is used as soon as possible (within 3 hours).
• Priporočljivo je, da se pripravljeno raztopino za infuzijo zdravila Remsima uporabi čimprej (v 3 urah).
Do not give this medicine to children and adolescents under 18 years of age because there are no data that show that this medicine is safe and works in this age group.
Tega zdravila ne smejo prejeti otroci in mladostniki, ki so mlajši od 18 let, saj ni na voljo nobenih podatkov, ki bi potrdili varnost in učinkovitost zdravila pri tej starostni skupini.
For women taking Remsima including those over 60 years of age, your doctor may recommend regular screening for cervical cancer.
Ženskam, ki prejemajo zdravilo Remsima, vključno s starejšimi od 60 let, lahko zdravnik priporoči redne presejalne teste za raka materničnega vratu.
After 4 weeks from the last intravenous infusion, you will be given Remsima via injection under the skin (subcutaneous injection).
4 tedne po zadnji intravenski infuziji boste zdravilo Remsima prejeli z injekcijo pod kožo (subkutano injiciranje).
Combined data from ACT 1 & 2
Združeni podatki iz študij ACT 1 in ACT 2
• In some patients receiving infliximab, the body may not make enough of the blood cells that help fight infections or help stop bleeding.
• Pri nekaterih bolnikih, ki prejemajo zdravilo Remsima, telo morda ne bo tvorilo dovolj krvnih celic, ki pomagajo v boju proti okužbam ali pri zaustavljanju krvavitve.
Remsima should only be used during pregnancy if your doctor feels it is necessary for you.
Zdravilo Remsima se lahko uporablja med nosečnostjo le, če zdravnik meni, da je to pri vas potrebno.
• Abnormal values of a blood protein called ‘complement factor' which is part of the immune system
• nenormalne vrednosti beljakovine v krvi, imenovane faktor komplementa, ki je del imunskega sistema
Keep this card with you for 4 months after your last dose of Remsima, or in case of pregnancy, for at least 6 months after the birth of your baby.
To kartico nosite s seboj še 4 mesece po zadnjem odmerku zdravila Remsima ali v primeru nosečnosti še vsaj 6 mesecev po rojstvu otroka.
Do not use Remsima if any of the above applies to you.
Ne uporabljajte zdravila Remsima, če menite, da se katero od zgoraj navedenih stanj nanaša na vas.
If acute reactions occur, medical treatment should be sought immediately.
Če se pojavi akutna reakcija, morate takoj poiskati zdravniško pomoč.
• If you experience reactivation of hepatitis B, your doctor may need to stop your treatment and may give you medicines such as effective antiviral therapy with supportive treatment.
• Če pri vas pride do reaktivacije hepatitisa B, bo zdravnik morda moral prekiniti vaše zdravljenje in vam dati zdravila, na primer za učinkovito protivirusno zdravljenje skupaj s podpornim zdravljenjem.
Interstitial lung disease (including rapidly progressive disease, lung fibrosis and pneumonitis)
intersticijska pljučna bolezen (vključno s hitro napredujočo boleznijo, pljučno fibrozo in pnevmonitisom)
Date of first authorisation: DD month YYYY
Datum prve odobritve: DD. mesec LLLL
a. Pull the olive green cap straight off and set it aside.
a. Olivno zelen pokrovček povlecite naravnost dol in ga odložite na stran.
Remsima is also used in adults and children 6 years of age or older for:
Zdravilo Remsima se uporablja tudi za zdravljenje odraslih in otrok starih 6 let in več za:
Between weeks 6 and 26, symptoms of psoriasis gradually returned with a median time to disease relapse of >20 weeks.
Med 6. in 26. tednom so se simptomi psoriaze postopoma povrnili, mediana vrednost časa do ponovitve bolezni pa je bila > 20 tednov.
a. After you hear the 2nd loud “click,” continue to hold the pen firmly against the skin and count slowly to at least five to ensure you inject the full dose.
a.Ko zaslišite glasen drugi klik«, še naprej trdno držite peresnik za kožo in počasi odštevajte vsaj pet, da zagotovite injiciranje celotnega odmerka.
Percentage ACR improvement
Odstotek izboljšanja ACR Srednja vrednost ± SDa
Sustained Steroid-Free Remissionb a Reduction in CDAI ≥25% and ≥70 points.
Ohranjena remisija brez jemanja steroidovb a Zmanjšanje CDAI na ≥ 25 % oziroma ≥ 70 točk.
Table 9 Effects on ACR and PASI in IMPACT and IMPACT 2
Učinki na ACR in PASI v študijah IMPACT in IMPACT 2
< 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data).
(≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti).
5 years at 2°C - 8°C.
5 let pri temperaturi 2°C - 8°C.
No dose adjustment is required (see section 5.2).
Prilagoditev odmerka zato ni potrebna (glejte poglavje 5.2).
Other medicines and Remsima
Druga zdravila in zdravilo Remsima
A damaged syringe may not function properly.
Poškodovana injekcijska brizga morda ne bo pravilno delovala.
Remsima and Orencia should not be used together.
Zdravili Remsima in Orencia se ne smeta uporabljati skupaj.
For storage conditions up to 25°C before reconstitution of the medicinal product, see section 6.3.
Za pogoje shranjevanja do 25°C pred rekonstitucijo zdravila glejte poglavje 6.3.
If you have used more Remsima than you should (either by injecting too much on a single occasion or by using it too frequently), talk to a doctor, pharmacist or nurse immediately.
Če ste uporabili prevelik odmerek zdravila Remsima Če ste uporabili večji odmerek zdravila Remsima, kot bi smeli (ali z enkratnim injiciranjem prevelikega odmerka ali prepogosto uporabo), se takoj posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
• After the first two intravenous infusions, the first dose of Remsima will be administered under the supervision of your doctor.
• Po prvih dveh intravenskih infuzijah boste prvi odmerek zdravila Remsima prejeli pod nadzorom svojega zdravnika.
• Tell your doctor if you have had treatment with medicines containing infliximab in the past and are now starting Remsima treatment again.
• Povejte zdravniku, če ste se v preteklosti že zdravili z zdravili, ki vsebujejo infliksimab in sedaj ponovno začenjate zdravljenje z zdravilom Remsima.
• The initial two intravenous infusions will be given to you by your doctor or nurse.
• Začetni dve intravenski infuziji vam bosta dala zdravnik ali medicinska sestra.
ACCENT I (Week-2 responders) % of Patients
ACCENT I (bolniki z odzivom v 2. tednu) % bolnikov
List of other medicines:
Seznam ostalih zdravil
Forty six percent of patients continued on stable doses of methotrexate (≤25 mg/week).
46 % bolnikov je zdravljenje nadaljevalo s stalnimi odmerki metotreksata (≤ 25 mg/teden).
c. Ensure you have the following supplies:
c. Pripravite si naslednje pripomočke:
The primary endpoint in both studies was the percent of patients who achieved ≥75% improvement in PASI from baseline at week 10.
Primarni končni rezultat v obeh študijah je bil odstotek bolnikov, ki so dosegli ≥ 75 % izboljšanje ocene PASI od začetne vrednosti v 10. tednu.
Remsima is not likely to affect your ability to drive or use tools or machines.
Zdravilo Remsima verjetno ne vpliva na vašo sposobnost vožnje in upravljanja z orodji ali stroji.
≥90% improvement ≥75% improvement ≥50% improvement
N ≥ 90 % izboljšanje ≥ 75 % izboljšanje ≥ 50 % izboljšanje
Remsima is produced in packs of 1, 2, 3, 4 or 5 vials.
Remsima je na voljo v pakiranjih po 1, 2, 3, 4 ali 5 vial.
• you have tuberculosis (TB) or another serious infection such as pneumonia or sepsis (serious bacterial infection of the blood),
• če imate tuberkulozo (TBC) ali katero drugo hudo okužbo, npr. pljučnico ali sepso (resno bakterijsko okužbo krvi),
An infusion-related reaction was defined in clinical studies as any adverse event occurring during an infusion or within 1 hour after an infusion.
Z infuzijo povezana reakcija je bila opredeljena v kliničnih študijah kot kateri koli neželeni učinek, ki je nastopil med infuzijo ali 1 uro po infuziji.
The following information is intended for healthcare professionals only: Patients treated with Remsima should be given the patient reminder card.
Naslednje informacije so namenjene samo zdravstvenemu osebju: Bolniki, ki se zdravijo z zdravilom Remsima, morajo prejeti opozorilno kartico za bolnika.
Patients in both studies had plaque psoriasis (Body Surface Area [BSA] ≥10% and Psoriasis Area and Severity Index [PASI] score ≥12).
Bolniki v obeh študijah so imeli psoriazo s plaki (telesna površina [BSA] ≥ 10 % in indeks površine in jakosti psoriaze [PASI] ≥ 12).
Remsima, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the improvement in physical function in:
Zdravilo Remsima je v kombinaciji z metotreksatom indicirano za zmanjšanje znakov in simptomov ter izboljšanje funkcije sklepov:
• The expiration date has passed.
• ima pretečen datum izteka roka uporabnosti.
2 weeks after your 1st dose
2 tedna po prvem odmerku tretji odmerek
b. Without pinching or stretching the skin, place the pen over the injection site at a 90-degree angle.
b. Ne da bi naredili kožno gubo ali kožo zgladili, injekcijski peresnik držite nad mestom injiciranja pod 90-stopinjskim kotom.
ACR 20 response*
ACR 20* Odziv
After the injection 12.
Po injiciranju 12.
Your doctor will advise you what other medicines you must keep using while you are having Remsima.
Zdravnik vam bo svetoval, katera zdravila morate še naprej jemati tudi med zdravljenjem z zdravilom Remsima.
Remsima is indicated for:
Zdravilo Remsima je indicirano za:
One serious infusion reaction (<1%) occurred in a patient on infliximab monotherapy.
Pojavila se je ena resna z infuzijo povezana reakcija (< 1 %), in sicer pri bolniku na monoterapiji z infliksimabom.
• Treatment with TNF blockers such as Remsima may result in reactivation of hepatitis B virus in patients who carry this virus, which can be life-threatening in some cases.
• Zdravljenje z zaviralci TNF, kot je zdravilo Remsima, lahko vodi do reaktivacije virusa hepatitisa B pri bolnikih, ki prenašajo ta virus, kar je lahko v nekaterih primerih življenjsko nevarno.
Infliximab should be administered intravenously over a 2 hour period.
Infliksimab je treba dajati intravensko v času 2 ur.
If you are not sure when to inject Remsima, call your doctor.
Če niste prepričani, kdaj si morate injicirati zdravilo Remsima, pokličite zdravnika.
Remsima contains sorbitol
Zdravilo Remsima vsebuje sorbitol
It is important to check the product labels to ensure that the correct formulation (intravenous or subcutaneous) is being administered to the patient, as prescribed.
Pomembno je, da preverite nalepko zdravila in zagotovite, da bolnik prejme ustrezno obliko (intravensko ali subkutano), ki mu je bila predpisana.
Each new injection site should be at least 3 cm away from the previous injection site.
Vsako novo mesto injiciranja mora biti od prejšnjega mesta oddaljeno vsaj 3 cm.
After the injection 13.
Po injiciranju 13.
• Remsima will be given to you by your doctor or nurse.
• Zdravilo Remsima vam bo dal zdravnik ali medicinska sestra.
The proportion of subjects who underwent colectomy at any time within 54 weeks following the first infusion of study agent were collected and pooled from the ACT 1 and ACT 2 studies and their extensions.
Podatke o odstotku preiskovancev, ki so jim opravili kolektomijo kadar koli v času 54 tednov po prvi infuziji proučevanega zdravila iz študij ACT 1 in ACT 2 ter njihovih podaljšanj, so zbrali in jih združili.
Table 5 Mean (SD) Actual Values of DAS28 (CRP and ESR)
Povprečne (SD) dejanske vrednosti DAS28 (CRP in ESR)
≥75% improvement
≥ 75 % izboljšanje
5 mg/kg (at week 24)
5 mg/kg (24 teden)
Most of these reactions were mild to moderate and resolved spontaneously without any treatment within a day.
Večina teh reakcij je bilo blagih do zmernih in so spontano izzvenele v enem dnevu brez kakršnega koli zdravljenja.
a. Pull the cap straight off and set it aside.
a. Pokrovček povlecite naravnost dol in ga odložite na stran.
Do not recycle the injecting device.
Pripomočka za injiciranje ne reciklirajte.
Therefore, subcutaneous use of Remsima is recommended for use only in adults.
Zato se uporaba zdravila Remsima v subkutani obliki priporoča samo pri odraslih bolnikih.
Note: After you remove the pen from the injection site, the needle will be automatically covered (see Figure I).
Opomba: Ko injekcijski peresnik umaknete z mesta injiciranja, se igla samodejno pokrije (glejte sliko I).
If you received Remsima while pregnant, giving BCG vaccine (used to prevent tuberculosis) to your baby within 6 months after birth may result in infection with serious complications, including death.
Če ste v času nosečnosti prejeli zdravilo Remsima, lahko cepljenje dojenčka s cepivom BCG (uporablja se za preprečevanje tuberkuloze) v obdobju 6 mesecev po rojstvu povzroči okužbo z resnimi zapleti, vključno s smrtjo.
Take your next dose on the next originally planned date and thereafter biweekly.
Naslednji odmerek vzemite naslednji prvotno načrtovani datum in nato vsaka dva tedna.
• These infections may be serious and include tuberculosis, infections caused by viruses, fungi, bacteria or other organisms in the environment and sepsis that may be life-threatening.
• Te okužbe so lahko resne in vključujejo tuberkulozo okužbe, ki jih povzročajo virusi, glive bakterije ali drugi organizmi iz okolja, ter sepso, kar je lahko življenjsko nevarno.
b. Keep holding the pen firmly against the skin and listen for the 2nd loud “click.”
b. Injekcijski peresnik še naprej držite trdno ob kožo in počakajte, dokler ne zaslišite glasnega drugega »klika«.
• Infection due to a live vaccine because of a weakened immune system.
• okužba zaradi živega cepiva zaradi oslabljenega imunskega sistema.
The incidence of anti-infliximab antibodies following the subcutaneous infliximab was demonstrated to be not higher than that of the intravenous infliximab and had no significant impact on efficacy (determined by disease activity score in 28 joints [DAS28] and American College of Rheumatology criteria 20 [ACR20]) and the safety profile.
Imunogenost Pojavnost protiteles proti infliksimabu po subkutanem dajanju infliksimaba ni bila višja kot po intravenskem dajanju infliksimaba ter ni imela nobenega pomembnega vpliva na učinkovitost (kot je bilo ugotovljeno z oceno aktivnosti bolezni v 28 sklepih [DAS28] in merilom ACR 20 Ameriškega revmatološkega združenja [ACR20]) in varnostni profil.
Remsima will generally be stored by the health professionals.
V glavnem bodo za shranjevanje zdravila Remsima poskrbeli zdravstveni delavci.
This includes multiple sclerosis, Guillain-Barré syndrome, if you have fits or have been diagnosed with ‘optic neuritis'.
To vključuje bolezni, kot so multipla skleroza, Guillain-Barréjev sindrom, če ste imeli napade krčev ali so vam diagnosticirali ″optični nevritis″.
In the event of an overdose, the patient should be treated symptomatically and supportive measures instituted as required.
V primeru prevelikega odmerjanja je treba bolnika zdraviti simptomatsko in poseči po ustreznih podpornih ukrepih.
What Remsima is and what it is used for
Kaj je zdravilo Remsima in za kaj ga uporabljamo
Antinuclear antibodies (ANA)/Anti-double-stranded DNA (dsDNA) antibodies
Protitelesa proti celičnemu jedru (ANA-anticelular antibodies)/protitelesa proti dvoverižni DNA (dsDNA)
a. After the syringe is empty, slowly lift your thumb from the plunger until needle is completely covered by the automatic needle guard.
a. Ko je injekcijska brizga prazna, palec počasi dvignite z bata, dokler igla ni v celoti pokrita s samodejnim ščitnikom za iglo.
a. Clean the injection site with an alcohol swab.
a. Mesto injiciranja očistite z alkoholnim zložencem.
Current data do not indicate that infliximab treatment influences the risk for developing dysplasia or colon cancer.
Dosedanji podatki ne kažejo, da da zdravljenje z infliksimabom vpliva na tveganje za nastanek displazije ali karcinoma kolona.
Infliximab is a monoclonal antibody - a type of protein that attaches to a specific target in the body called TNF (tumour necrosis factor) alpha.
Infliksimab je monoklonsko protitelo - Vrsta beljakovine, ki se veže na določeno tarčo v telesu, imenovano TNF (tumorje nekrotizirajoči faktor).
Hypersensitivity to the active substance, to other murine proteins or to any of the excipients listed in section 6.1.
Preobčutljivost na učinkovino, druge glodalske beljakovine ali katero koli pomožno snov, navedeno v poglavju 6.1.
Talk to your doctor if you are on a low salt diet.
če ste na dieti z zmanjšanim vnosom soli.
• Your doctor will also give you a patient reminder card, which contains important safety information you need to be aware of before and during your treatment with Remsima.
• Zdravnik vam bo dal tudi opozorilno kartico za bolnika, na kateri so navedeni pomembnejši varnostni podatki, ki jih morate poznati, preden prejmete zdravilo Remsima in tudi med zdravljenjem z njim.
Vaccine breakthrough infection (after in utero exposure to infliximab)*.
okužba po cepljenju (po in utero izpostavitvi infliksimabu)*
ACR response (% of patients) N
Odziv ACR (% bolnikov) N
• Children should receive recommended vaccinations before starting Remsima treatment.
• Otroci morajo prejeti priporočena cepljenja, preden se začnejo zdraviti z zdravilom Remsima.
A total of 573 patients with moderately to severely active Crohn's disease (CDAI ≥220 ≤400) received a single infusion of 5 mg/kg at week 0.
Skupaj 573 bolnikov z zmerno do hudo aktivno Crohnovo boleznijo (CDAI ≥ 220 ≤ 400) je prejelo enkratno infuzijo odmerka 5 mg/kg v tednu 0.
• A reminder to patients to show the patient reminder card to all treating HCPs, including in conditions of emergency, and a message for HCPs that the patient is using Remsima
• Opomnik za bolnike, da morajo pokazati opozorilno kartico za bolnika vsem zdravstvenim delavcem, ki sodelujejo pri zdravljenju (tudi v nujnih stanjih) ter sporočilo za zdravstvene delavce, da bolnik uporablja zdravilo Remsima.
There are no known side effects of having too much of Remsima.
Ni poznanih neželenih učinkov zaradi prejetja prevelikega odmerka zdravila Remsima.
All systemic injection reactions were mild to moderate.
Vse sistemske z injiciranjem povezane reakcije so bile blage do zmerne.
You will find detailed “Instructions for Use” at the end of this leaflet.
Na koncu tega listka so podrobna »Navodila za uporabo zdravila«.
The dose and the number of Remsima vials have to be calculated.
Odmerek in število potrebnih vial zdravila Remsima morate izračunati.
• Tell your surgeon or dentist that you are having treatment with Remsima by showing them your patient reminder card.
• Obvestite kirurga ali zobozdravnika, da prejemate zdravilo Remsima in mu pokažite svojo opozorilno kartico za bolnika.
While using Remsima you should not receive live vaccines.
Med uporabo zdravila Remsima ne smete prejeti živih cepiv.
Neoplasms benign, malignant and unspecified (including cysts and polyps) Rare:
Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi)
The safety profile of Remsima subcutaneous formulation in combination with methotrexate was evaluated in a Phase I/III parallel group study in patients with active rheumatoid arthritis.
Varnostni profil zdravila Remsima v subkutani obliki skupaj z metotreksatom so ocenjevali v študiji faze I/III pri vzporednih skupinah pri bolnikih z aktivnim revmatoidnim artritisom.
The bioavailability of infliximab subcutaneous, estimated in a population PK model, is 58% (95% CI:
Biološka razpoložljivost infliksimaba subkutano, ocenjena na populacijskem modelu farmakokinetike, je 58 % (95 % CI: 54 % - 62 %).
In general, patients who developed ALT and AST elevations were asymptomatic, and the abnormalities decreased or resolved with either continuation or discontinuation of infliximab, or modification of concomitant therapy.
Na splošno bolniki, pri katerih se je pojavilo zvišanje ALT in AST, niso imeli simptomov in nenormalni izvidi so se zmanjšali ali normalizirali bodisi z nadaljevanjem ali z ukinitvijo zdravljenja z infliksimabom, ali ob prilagoditvi drugih sočasnih terapij.
Remsima belongs to a group of medicines called ‘TNF blockers'.
Zdravilo Remsima spada v skupino zdravil, ki se imenujejo "zaviralci TNF".
The physician should ensure appropriate follow-up of patients for any systemic injection reaction and localised injection site reaction after the initial subcutaneous injection is administered.
Zdravnik mora zagotoviti ustrezno spremljanje bolnikov zaradi morebitnih sistemskih z injiciranjem povezanih reakcij in lokalnih reakcij na mestu injiciranja po začetnem subkutanem injiciranju.
Single doses up to 20 mg/kg have been administered without toxic effects.
Uporabljeni so bili enkratni odmerki infliksimaba do 20 mg/kg, ki niso povzročili toksičnih učinkov.
Contents of the pack and other information What Remsima contains
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Remsima
Remsima may have a minor influence on the ability to drive and use machines.
Zdravilo Remsima ima lahko blag vpliv na sposobnost vožnje in upravljanja strojev.
Children may receive some vaccines during treatment with Remsima but should not receive live vaccines while using Remsima.
Otroci lahko med zdravljenjem z zdravilom Remsima prejmejo nekatera cepiva, vendar med uporabo zdravila Remsima ne smejo prejeti živih cepiv.
b. Using your other hand, gently pinch a fold of skin you cleaned.
b. Z drugo roko nežno naredite kožno gubo na mestu, kjer ste kožo očistili.
Subcutaneous administration of Remsima is not recommended for paediatric use and no data are available on the use of Remsima administered subcutaneously in the paediatric population.
Subkutano dajanje zdravila Remsima pri pediatrični populaciji ni priporočeno in ni na voljo nobenih podatkov o uporabi zdravila Remsima subkutano pri pediatrični populaciji.
Table 4 Effects on ACRn, Structural Joint Damage and Physical Function at week 54, ASPIRE
Učinki na ACRn, strukturno poškodbo sklepov in funkcijo sklepov v 54. tednu, ASPIRE
ACR 50 response*
ACR 50* Odziv
This Patient Reminder Card contains important safety information that you need to be aware of before and during treatment with Remsima.
Ta opozorilna kartica za bolnika vsebuje pomembne varnostne informacije, ki jih morate poznati preden prejmete zdravilo Remsima, ter med zdravljenjem z njim.
* Infliximab is a chimeric human-murine IgG1 monoclonal antibody produced in murine hybridoma cells by recombinant DNA technology.
* Infliksimab je himerno humano-glodalsko monoklonsko protitelo IgG1, pridobljeno iz celic glodalskega hibridoma s tehnologijo rekombinantne DNK.
The required volume of reconstituted Remsima solution should slowly be added to the 250-mL infusion bottle or bag and gently be mixed.
Potrebni volumen rekonstituirane raztopine zdravila Remsima morate počasi dodajati v 250-ml infuzijske steklenice ali vrečke in rahlo premešati.
Do not warm the syringe using heat sources such as hot water or a microwave.
Injekcijske brizge ne smete segrevati z viri toplote, kot je topla voda ali mikrovalovna pečica.
The proportion of patients with infections in C0168T72 was similar to that in the paediatric Crohn's disease study (REACH) but higher than the proportion in the adults ulcerative colitis studies (ACT 1 and ACT 2).
Delež bolnikov z okužbami je bil v preskušanju C0168T72 podoben kot v študiji Crohnove bolezni pri pediatričnih bolnikih (REACH), a večji od deleža v študijah ulceroznega kolitisa pri odraslih bolnikih (ACT 1 in